782-08-1

Usage

Uses

Used in Pharmaceutical Industry:
1,1'-(chloromethylene)bis[4-chlorobenzene] is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing ones.
Used in Agrochemical Industry:
1,1'-(chloromethylene)bis[4-chlorobenzene] serves as an essential building block in the production of agrochemicals, aiding in the development of effective pesticides and other agricultural chemicals to protect crops and enhance agricultural productivity.
Used in Dye and Pigment Industry:
1,1'-(chloromethylene)bis[4-chlorobenzene] is utilized as an intermediate in the manufacturing of dyes and pigments, playing a crucial role in creating vibrant colors and shades for various applications, including textiles, plastics, and printing inks.
Used in Polymer Industry:
As an intermediate in polymer synthesis, 1,1'-(chloromethylene)bis[4-chlorobenzene] contributes to the development of new polymer materials with improved properties, such as enhanced strength, durability, and resistance to environmental factors.
However, it is crucial to handle 1,1'-(chloromethylene)bis[4-chlorobenzene] with care due to its toxic nature to aquatic life and potential to cause skin irritation and respiratory problems in humans if not managed properly. Additionally, its persistence in the environment and non-readily biodegradable nature pose potential long-term risks, necessitating responsible use and disposal practices.

Upstream product

• 101-76-8 4,4'-dichlorodiphenylmethane 
• 90-97-1 4,4'-dichlorobenzophenone 
• 119-56-2 (4-chlorophenyl)phenylmethanol 
• 4732-69-8 Chloro-oxo-acetic acid 
• 90-98-2 4,4'-Dichlorobenzophenone 
• 7647-01-0 hydrogenchloride 
• 71-43-2 benzene 

Downstream Products

• 27469-61-0 1-(4,4'-dichloro-benzhydryl)-piperazine 
• 101784-44-5 1-(bis(4-chlorophenyl)methyl)-4-methylpiperazine 
• 107866-47-7 (4,4'-dichloro-benzhydryl)-malonic acid diethyl ester 
• 13144-33-7 1,1,2,2-tetrakis(4-chlorophenyl)ethane 
• 19685-62-2 N,N-dimethyl[bis(4-chlorophenyl)methyl]amine 
• 635320-01-3 bis(4-chlorophenyl)methanethiol 
• 123124-74-3 1-[Bis-(4-chloro-phenyl)-methyl]-pyrrolidine 
• 102993-59-9 1-[bis-(4-chlorophenyl)methyl]imidazole 
• 103294-87-7 1-[bis(4-chlorophenyl)methyl]-1H-1,2,3-triazole 
• 123124-55-0 2-[bis(4-chlorophenyl)methyl]-2H-1,2,3-triazole 
• 102994-04-7 1--1H-1,2,4-triazole 
• 102994-05-8 4--4H-1,2,4-triazole 
• 90-97-1 4,4'-dichlorobenzophenone 
• 55702-41-5 Bis(4-chlorophenyl)methyl methyl ether 

Relevant academic research and scientific papers

Capture of benzhydryl chloride ion pairs by cobalt nitrate

A case is presented where a transition metal salt, Co(NO3)2, intervenes in the solvolysis of benzhydryl chloride, after the rate determining ionization step. This is in contrast to the behavior of other salts which intervene early and promote the ionization reaction. This novel behavior of Co(NO3)2 permits for the first time the detection of two ion pair intermediates in the solvolysis of an alkyl chloride which generates an open carbonium ion.

Synthesis and biological evaluation of 1‐(Diarylmethyl)‐1h‐1,2,4‐triazoles and 1‐(diarylmethyl)‐1h‐imidazoles as a novel class of anti‐mitotic agent for activity in breast cancer

We report the synthesis and biochemical evaluation of compounds that are designed as hybrids of the microtubule targeting benzophenone phenstatin and the aromatase inhibitor letrozole. A preliminary screening in estrogen receptor (ER)‐positive MCF‐7 breast cancer cells identified 5‐((2H‐1,2,3‐triazol‐1‐yl)(3,4,5‐trimethoxyphenyl)methyl)‐2‐methoxyphenol 24 as a potent antiproliferative compound with an IC50 value of 52 nM in MCF‐7 breast cancer cells (ER+/PR+) and 74 nM in triple‐negative MDA‐MB‐231 breast cancer cells. The compounds demonstrated significant G2/M phase cell cycle arrest and induction of apoptosis in the MCF‐7 cell line, inhibited tubulin polymerisation, and were selective for cancer cells when evaluated in non-tumorigenic MCF‐10A breast cells. The immunofluorescence staining of MCF‐7 cells confirmed that the compounds targeted tubulin and induced multinucleation, which is a recognised sign of mitotic catastrophe. Computational docking studies of compounds 19e, 21l, and 24 in the colchicine binding site of tubulin indicated potential binding conformations for the compounds. Compounds 19e and 21l were also shown to selectively inhibit aromatase. These compounds are promising candidates for development as antiproliferative, aromatase inhibitory, and microtubule‐disrupting agents for breast cancer.

HETEROCYCLICALKYL DERIVATIVE COMPOUNDS AS SELECTIVE HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.

Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

Recently, we reported that chlorcyclizine (CCZ, Rac-2), an over-the-counter antihistamine piperazine drug, possesses in vitro and in vivo activity against hepatitis C virus. Here, we describe structure-activity relationship (SAR) efforts that resulted in the optimization of novel chlorcyclizine derivatives as anti-HCV agents. Several compounds exhibited EC50 values below 10 nM against HCV infection, cytotoxicity selectivity indices above 2000, and showed improved in vivo pharmacokinetic properties. The optimized molecules can serve as lead preclinical candidates for the treatment of hepatitis C virus infection and as probes to study hepatitis C virus pathogenesis and host-virus interaction.

Phosphine functionalized polyphosphazenes: soluble and re-usable polymeric reagents for highly efficient halogenations under Appel conditions

In this paper we present the preparation and application of a novel soluble phosphine functionalized polyphosphazene (poly[3-(diphenylphosphino)propylamino]phosphazene) and investigate its application as a polymeric reagent. Upon chlorination of the pendant phosphine groups, the polymer was found to facilitate the rapid and efficient transformation of alcohols to the corresponding chlorides and bromides under Appel-type conditions. Reaction times followed by 31P NMR spectroscopy are shown to be rapid (several minutes) and the yields for the transformation of alcohols to the corresponding halides are in the range 80–99?%. The facile recovery of the oxidized polymeric agent by precipitation is also described, offering a significant advantage over notoriously difficult to remove small molecule phosphine oxide by-products. Furthermore the regeneration of the reactive phosphine chloride pendant groups is demonstrated, which could be efficiently re-used in a further chlorination reaction. Graphical abstract: [Figure not available: see fulltext.]

PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF

The invention provides pyrrolo-pyrrole carbamate and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., solid tumor cancer, obesity, Down's syndrome, Alzheimer's disease, or pain, in a patient. The octahydropyrrolo pyrrole carbamates could be derived from hexafluoroisopropanol, Ν,Ν-disuccinimide and such. The activity of carbamates in MAGL, FAAH, and ABHD6 assays are also described.

PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER

Disclosed are compounds of formula (I) (formula I),as antiviral agents, antineoplastic agents, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X and Y are independently CH or N, o is 0, 1 or 2, and E is absent or is (CR13 R14 )m, NH, or S, F is absent or is (CR15 R16 )n, C=O, or -SO2 -, G is absent or is (CR17 CR18 )r, H is absent or is C=O, or -SO2 - and R1, Ar1, Ar2 are as defined in the specification. These compounds are antiviral agents and are contemplated in the treatment of viral infections, for example, hepatitis C, or are antineoplastic agents.

Chlorination of benzylic and allylic alcohols with trimethylsilyl chloride enhanced by natural sodium montmorillonite

A new and practical method for the efficient chlorination of tertiary, secondary, and primary benzylic and allylic alcohols is described. The method is characterized by the formation of hydrogen chloride from trimethylsilyl chloride and trace water, the formation of a carbenium ion through the protonation of an alcohol and subsequent dehydration, and the chlorination of the carbenium ion. During the process, sodium ion-exchanged montmorillonite plays a crucial role in capturing the generated hydrogen chloride, stabilizing the carbenium intermediate as well as promoting the chlorination.

CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

Development of small-molecule probes that selectively kill cells induced to express mutant RAS

Synthetic lethal screening is a chemical biology approach to identify small molecules that selectively kill oncogene-expressing cell lines with the goal of identifying pathways that provide specific targets against cancer cells. We performed a high-throughput screen of 303,282 compounds from the National Institutes of Health-Molecular Libraries Small Molecule Repository (NIH-MLSMR) against immortalized BJ fibroblasts expressing HRASG12V followed by a counterscreen of lethal compounds in a series of isogenic cells lacking the HRASG12V oncogene. This effort led to the identification of two novel molecular probes (PubChem CID 3689413, ML162 and CID 49766530, ML210) with nanomolar potencies and 4-23-fold selectivities, which can potentially be used for identifying oncogene-specific pathways and targets in cancer cells.